We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.625 | 3.50 | 3.75 | 3.625 | 3.625 | 3.625 | 20,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.38 | 3.26M |
TIDMVAL
RNS Number : 1088V
ValiRx PLC
23 October 2014
23 October 2014
ValiRx Plc
("ValiRx" or the "Company")
Grant of options
ValiRx Plc (AIM: VAL), the AIM-quoted life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 22 October 2014, it granted 149,000,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
Name of Number % of Number Number Total Options director of shares issued of existing of new options held held share options options now held as % capital granted of issued share capital Satu Vainikka 23,113,714 0.79% 35,000,000 24,000,000 59,000,000 2.02% George Morris 18,535,993 0.63% 28,750,000 22,000,000 50,750,000 1.74% Gerry Desler 12,733,921 0.44% 28,400,000 22,000,000 50,400,000 1.73% Kevin Alexander 8,034,843 0.28% 26,400,000 20,000,000 46,400,000 1.59% Oliver de Giorgio-Miller 2,444,411 0.08% 23,000,000 20,000,000 43,000,000 1.47% Seppo Makinen 1,273,387 0.04% 8,000,000 20,000,000 28,000,000 0.96% ----------- --------- ------------- ------------ ------------ ----------- Total Directors 66,136,269 2.26% 149,550,000 128,000,000 277,550,000 9.51% Other employees Nil Nil 23,100,000 21,000,000 44,100,000 1.51% Total 66,136,269 2.26% 172,650,000 149,000,000 321,650,000 11.02% ----------- --------- ------------- ------------ ------------ -----------
The new options were granted under the Company's stock option plan and have an exercise price of 0.36p pence. The new options are exercisable from 22 October 2014 until 21 October 2024.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors, which could be issued, is 277,550,000 Ordinary Shares, representing approximately 9.51 per cent. of the current issued share capital of the Company.
In addition, a further 21,000,000 options have been granted to employees of the Company at an exercise price of 0.36 pence which are exercisable until 21 October 2024.
The issued share capital of the Company comprises 2,921,043,420 ordinary shares of 0.1 pence each.
For more information, please contact:
ValiRx plc Tel: +44 (0)20 3008 4416 Dr Satu Vainikka www.ValiRx.com Cairn Financial Advisers Tel: +44 (0)20 7148 LLP (Nominated Adviser) 7900 Liam Murray / Avi Robinson Daniel Stewart & Company Tel: +44 (0)20 7776 Plc (Broker) 6550 Martin Lampshire/ Mark Treharne Peckwater PR Tel: +44 (0)7879 458 364 Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSGCBDGGSDBGSX
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions